166 related articles for article (PubMed ID: 29267448)
1. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome.
Polat AK; Belli AA; Karakus V; Dere Y
An Bras Dermatol; 2017; 92(5 Suppl 1):59-61. PubMed ID: 29267448
[TBL] [Abstract][Full Text] [Related]
2. A maculopapular-type eruption associated with deferasirox administration.
Ohshita A; Nakai N; Katoh N; Konishi K
J Am Acad Dermatol; 2013 Nov; 69(5):e265-e267. PubMed ID: 24124858
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
5. Acute interstitial nephritis due to deferasirox: a case report.
Brosnahan G; Gokden N; Swaminathan S
Nephrol Dial Transplant; 2008 Oct; 23(10):3356-8. PubMed ID: 18653899
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.
Nolte F; Angelucci E; Beris P; Macwhannell A; Selleslag D; Schumann C; Xicoy B; Almeida A; Guerci-Bresler A; Sliwa T; Muus P; Porter J; Hofmann WK
Leuk Res; 2011 Sep; 35(9):1131-5. PubMed ID: 21737138
[TBL] [Abstract][Full Text] [Related]
7. First report of drug-induced esophagitis by deferasirox.
Yoshikawa T; Hara T; Araki H; Tsurumi H; Oyama M; Moriwaki H
Int J Hematol; 2012 Jun; 95(6):689-91. PubMed ID: 22547195
[TBL] [Abstract][Full Text] [Related]
8. Severe hypocalcemia and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome under deferasirox therapy for myelodysplasic syndrome.
Said BB; Rozieres A; Martin O; Nicolas JF; Berard F
Am J Hematol; 2012 Feb; 87(2):233. PubMed ID: 22120845
[No Abstract] [Full Text] [Related]
9. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Breccia M; Finsinger P; Loglisci G; Federico V; Santopietro M; Colafigli G; Petrucci L; Salaroli A; Serrao A; Latagliata R; Alimena G
Ann Hematol; 2012 Sep; 91(9):1345-9. PubMed ID: 22569854
[TBL] [Abstract][Full Text] [Related]
10. Reversible Fanconi syndrome in a pediatric patient on deferasirox.
Rheault MN; Bechtel H; Neglia JP; Kashtan CE
Pediatr Blood Cancer; 2011 Apr; 56(4):674-6. PubMed ID: 21298760
[TBL] [Abstract][Full Text] [Related]
11. CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.
Bruch HR; Dencausse Y; Heßling J; Michl G; Schlag R; Skorupa A; Schneider-Schranz C; Wolf S; Schulte C; Tesch H
Oncol Res Treat; 2016; 39(7-8):424-31. PubMed ID: 27486873
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
13. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
[TBL] [Abstract][Full Text] [Related]
14. Enalapril induced normocomplementemic urticarial vasculitis.
Koregol S; Naidu V; Rao S; Ankad BS
Indian J Dermatol Venereol Leprol; 2015; 81(1):73-4. PubMed ID: 25566910
[No Abstract] [Full Text] [Related]
15. Urticarial vasculitis due do infliximab.
Goulão J; Cunha H; Anes I; Bártolo E; Furtado C; Serrano P; Brandão FM
J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):882-3. PubMed ID: 18462298
[No Abstract] [Full Text] [Related]
16. Clinical application of deferasirox: practical patient management.
Vichinsky E
Am J Hematol; 2008 May; 83(5):398-402. PubMed ID: 18058997
[TBL] [Abstract][Full Text] [Related]
17. Updated recommendations on the management of gastrointestinal disturbances during iron chelation therapy with Deferasirox in transfusion dependent patients with myelodysplastic syndrome - Emphasis on optimized dosing schedules and new formulations.
Nolte F; Angelucci E; Breccia M; Gattermann N; Santini V; Vey N; Hofmann WK
Leuk Res; 2015 Oct; 39(10):1028-33. PubMed ID: 26293555
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of deferasirox.
Cappellini MD
Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
[TBL] [Abstract][Full Text] [Related]
20. A case report of deferasirox-induced kidney injury and Fanconi syndrome.
Murphy N; Elramah M; Vats H; Zhong W; Chan MR
WMJ; 2013 Aug; 112(4):177-80. PubMed ID: 24734408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
